Oruka Therapeutics, Inc.

NASDAQ: ORKA · Healthcare · Biotechnology

PublicHQ Menlo Park, MACIK 0000907654Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

65B

FH 66DQ 60GM —SS 74

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$105.4M

Employees

Market cap

$3.2B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02023

Net income-$105.4M-$105.4M2025

Operating income-$122.1M-$122.1M2025

Total assets$488.6M$488.6M2025

Liabilities$16.7M$16.7M2025

Equity$471.9M$471.9M2025

Revenue trend

FY2016 – FY2023 · USD

FY16

FY17

FY18

FY19

FY20

FY21

FY22

FY23

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Oruka Therapeutics, Inc. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Arcutis Biotherapeutics, Inc.66B Integer Holdings Corporation84B+Relay Therapeutics, Inc.58C Alumis Inc.35D

Key facts

CEOLawrence Otto Klein

SectorHealthcare

IndustryBiotechnology

HeadquartersMenlo Park, MA

ExchangeNASDAQ: ORKA

Employees28

IPO date1997-08-08

Latest filings

8-K2026-06-04 8-K2026-06-01 10-Q2026-05-13 8-K2026-04-30 8-K2026-04-27 DEF 14A2026-04-17 10-K2026-03-12 8-K2025-12-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.